Empros Pharma AB is a Swedish AB based in Solna, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2013, the company reported a gross profit of SEK 8.3m in its latest annual filing.
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget har till föremål för sin verksamhet att utveckla och marknadsföra läkemedel samt att bedriva därmed förenlig verksamhet.
In its most recent annual report (2025), Empros Pharma AB reported a gross profit of SEK 8.3m, an increase of 4% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of SEK 14.8m, and the EBITDA margin stood at -161.6%.
At the end of 2025, equity financed 80.7% of the balance sheet, and current assets covered short-term debt 0.4 times.
Frequently asked questions
What is the Org number of Empros Pharma AB?
Empros Pharma AB is registered with Bolagsverket / SCB under Org 5569453862.
What is the gross profit of Empros Pharma AB?
Empros Pharma AB reported a gross profit of SEK 8.3m in 2025.
Who is the CEO of Empros Pharma AB?
Jan Arvid Söderhäll is the CEO of Empros Pharma AB, in role since 2020.
Who is the chairman of Empros Pharma AB?
Eugen Steiner chairs the board of Empros Pharma AB, in role since 2022.
Where is Empros Pharma AB headquartered?
Empros Pharma AB's registered address is Nanna Svartz Väg 4.
